Moderna and Merck shares soar on mRNA cancer vaccine
- Merck: 2 events in the last 90 days
What happened
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rew…
Summary assembled by rule from the sources below